These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 6592037

  • 1. Effect of the interval between exposures to cytarabine on its cytotoxic action on HL-60 myeloid leukemic cells.
    Leclerc JM, Momparler RL.
    Cancer Treat Rep; 1984 Sep; 68(9):1143-8. PubMed ID: 6592037
    [Abstract] [Full Text] [Related]

  • 2. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K, Nayak R, Grant S.
    Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
    [Abstract] [Full Text] [Related]

  • 3. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
    Grant S, Bhalla K, Rauscher F, Cadman E.
    Cancer Res; 1983 Nov; 43(11):5093-100. PubMed ID: 6577943
    [Abstract] [Full Text] [Related]

  • 4. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
    Colly LP, Peters WG, Willemze R.
    Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691
    [Abstract] [Full Text] [Related]

  • 5. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T, Negoro E, Kishi S, Takagi K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.
    Biochem Pharmacol; 2009 Jun 15; 77(12):1780-6. PubMed ID: 19428333
    [Abstract] [Full Text] [Related]

  • 6. Deoxyguanosine enhancement of cytarabine nucleotide accumulation in human leukemia cells.
    Akman SA, Ross DD, Joneckis CC, Fox BM, Bachur NR.
    Cancer Treat Rep; 1985 Jun 15; 69(7-8):851-7. PubMed ID: 4016794
    [Abstract] [Full Text] [Related]

  • 7. Metabolism, incorporation into DNA, and interactions with 1-beta-D-arabinofuranosylcytosine of 5-hydroxymethyl-2'-deoxyuridine in human promyelocytic leukemia cells (HL-60).
    Vilpo JA, Vilpo LM.
    Cancer Res; 1988 Jun 01; 48(11):3117-22. PubMed ID: 3163271
    [Abstract] [Full Text] [Related]

  • 8. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF, Huang P, Plunkett W, Gandhi V.
    Clin Cancer Res; 1996 Apr 01; 2(4):653-8. PubMed ID: 9816215
    [Abstract] [Full Text] [Related]

  • 9. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
    Boos J, Hohenlöchter B, Schulze-Westhoff P, Schiller M, Zimmermann M, Creutzig U, Ritter J, Jurgens H.
    Med Pediatr Oncol; 1996 Jun 01; 26(6):397-404. PubMed ID: 8614376
    [Abstract] [Full Text] [Related]

  • 10. Characterization of tumor cell heterogeneity of a murine leukemia cell line (L1210) in response to arabinosylcytosine: quantitation using a computerized image analysis system.
    Raymakers RA, Slocum HK, Minderman H, Malmberg M, Rustum YM.
    Exp Hematol; 1993 May 01; 21(5):602-7. PubMed ID: 8513859
    [Abstract] [Full Text] [Related]

  • 11. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb 01; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 12. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine.
    Capizzi RL, White JC, Powell BL, Perrino F.
    Semin Hematol; 1991 Jul 01; 28(3 Suppl 4):54-69. PubMed ID: 1780754
    [Abstract] [Full Text] [Related]

  • 13. Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in acute myelocytic leukemia cells in culture.
    Fountzilas G, Inoue S, Ohnuma T.
    Leukemia; 1990 May 01; 4(5):321-4. PubMed ID: 2388478
    [Abstract] [Full Text] [Related]

  • 14. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
    Abe I, Saito S, Hori K, Suzuki M, Sato H.
    Cancer Res; 1982 Jul 01; 42(7):2846-51. PubMed ID: 7083175
    [Abstract] [Full Text] [Related]

  • 15. Differential effect of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells.
    Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Safah H, Graham G.
    Exp Hematol; 1991 Aug 01; 19(7):669-73. PubMed ID: 1893953
    [Abstract] [Full Text] [Related]

  • 16. [Detection of the resistance to Ara-C blast cells in acute myeloid leukemia using flow cytometry].
    Lacombe F, Belloc F, Dumain P, Puntous M, Cony-Makhoul P, Bernard P, Boisseau MR, Reiffers J.
    Bull Cancer; 1995 Aug 01; 82(5):349-56. PubMed ID: 7626842
    [Abstract] [Full Text] [Related]

  • 17. Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.
    Grant S, Turner AJ, Bartimole TM, Nelms PA, Joe VC, Jarvis WD.
    Oncol Res; 1994 Aug 01; 6(2):87-99. PubMed ID: 7949469
    [Abstract] [Full Text] [Related]

  • 18. [Is the pharmacokinetic profile of cytarabine clinically relevant?].
    Boos J.
    Klin Padiatr; 1992 Aug 01; 204(4):198-203. PubMed ID: 1518256
    [Abstract] [Full Text] [Related]

  • 19. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI, Powell W.
    Cancer Invest; 1987 Aug 01; 5(4):293-9. PubMed ID: 3664332
    [Abstract] [Full Text] [Related]

  • 20. In vitro biochemical and cytotoxicity studies with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine in combination.
    Momparler RL, Goodman J, Karon M.
    Cancer Res; 1975 Oct 01; 35(10):2853-7. PubMed ID: 50882
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.